Hereditary Angioedema (HAE) - Pipeline Review, H1 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Pipeline Review, H1 2017, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) (Immunology) pipeline landscape.
Hereditary angioedema (HAE) is a rare inherited disease that causes considerable swelling in various body tissues, su
Read More
- List of Tables
- Number of Products under Development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), H1 2017
- Number of Products under Development by Companies, H1 2017
- Products under Development by Companies, H1 2017
- Products under Development by Companies, H1 2017 (Contd..1), H1 2017
- Number of Products by Stage and Target, H1 2017
- Number of Products by Stage and Mechanism of Action, H1 2017
- Number of Products by Stage and Route of Administration, H1 2017
- Number of Pr
Read More
- Table of Contents
- List of Tables
- List of Figures
- Introduction
- Global Markets Direct Report Coverage
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Overview
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mecha
Read More